Mayne Pharma Group Limited

ASX:MYX Stock Report

Market Cap: AU$397.6m

Mayne Pharma Group Management

Management criteria checks 1/4

Mayne Pharma Group's CEO is Shawn O’Brien, appointed in Oct 2022, has a tenure of 2.17 years. total yearly compensation is A$2.06M, comprised of 46.5% salary and 53.5% bonuses, including company stock and options. directly owns 0.075% of the company’s shares, worth A$298.22K. The average tenure of the management team and the board of directors is 2.9 years and 2.8 years respectively.

Key information

Shawn O’Brien

Chief executive officer

AU$2.1m

Total compensation

CEO salary percentage46.5%
CEO tenure2.2yrs
CEO ownership0.07%
Management average tenure2.9yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01
A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Dec 03
Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Dec 01
Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Apr 12
Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16
We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10
Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17
Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22
Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01
How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08
What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18
Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27
Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09
Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24
A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

CEO Compensation Analysis

How has Shawn O’Brien's remuneration changed compared to Mayne Pharma Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$2mAU$959k

-AU$169m

Mar 31 2024n/an/a

-AU$221m

Dec 31 2023n/an/a

-AU$274m

Sep 30 2023n/an/a

-AU$296m

Jun 30 2023AU$2mAU$663k

-AU$317m

Compensation vs Market: Shawn's total compensation ($USD1.31M) is above average for companies of similar size in the Australian market ($USD703.61K).

Compensation vs Earnings: Shawn's compensation has increased whilst the company is unprofitable.

CEO

Shawn O’Brien (65 yo)

2.2yrs

Tenure

AU$2,062,194

Compensation

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Leadership Team

NamePositionTenureCompensationOwnership
Shawn O’Brien
CEO, MD & Director2.2yrsAU$2.06m0.075%
A$ 298.2k
Aaron Gray
Chief Financial Officer2.3yrsAU$1.31m0.064%
A$ 253.2k
Kimberly Parker
Executive VP & General Counsel2.9yrsno datano data
Brant Schofield
Executive Vice President of Corporate Development3.9yrsAU$1.29mno data
Erinn Nathaniel
Director of Global Human Resources1.9yrsno datano data
Daniel Moore
Executive Vice President of Commercial5.3yrsno datano data
Frank Casty
Executive VP & Global Chief Medical Officer1.9yrsno datano data
Brenton Walter
Financial Controller20.4yrsno datano data
Laura Loftus
Associate General Counsel & Company Secretary4.8yrsno datano data

2.9yrs

Average Tenure

Experienced Management: MYX's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shawn O’Brien
CEO, MD & Director2.2yrsAU$2.06m0.075%
A$ 298.2k
Frank Condella
Independent Non-Executive Chairman6.6yrsAU$305.40k0.081%
A$ 323.1k
Bruce Robinson
Independent Non-Executive Director10.3yrsAU$219.39k0.039%
A$ 155.6k
Patrick Blake
Independent Non-Executive Director6.5yrsAU$218.36k0.027%
A$ 108.3k
Ann Custin
Independent Non-Executive Director2.8yrsAU$235.16k0.026%
A$ 104.7k
Kathryn MacFarlane
Independent Non-Executive Director2.8yrsAU$215.84k0.047%
A$ 186.2k
Anne Lockwood
Independent Non Executive Director1.1yrsAU$117.49kno data
David Petrie
Non-Executive Director2.3yrsAU$217.86kno data

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: MYX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 02:41
End of Day Share Price 2024/12/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayne Pharma Group Limited is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightAPP Securities Pty Ltd.
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter